6533b85afe1ef96bd12b94da

RESEARCH PRODUCT

Extrasystolie während extrakorporaler biliärer Stoßwellenlithotripsie: Inzidenz und klinische Bedeutung*

A. GrosseMeyer Zum Büschenfelde KhTreese NStaritz MKenneth H. MayerA. Rambow

subject

business.industrymedicine.medical_treatmentIncidence (epidemiology)General MedicineLithotripsyExtracorporealPethidineBlood pressureNifedipineAnesthesiamedicineClinical significancebusinessShockwave lithotripsymedicine.drug

description

Incidence and clinical significance of cardiac side effects of extracorporeal shock-wave lithotripsy (ESWL) were prospectively analysed for 85 patients (26 men, 59 women; mean age 44 [17-81] years) with cholecystolithiasis (n = 70) or choledocholithiasis (n = 15). 24-hour ECG monitoring was undertaken on the day of treatment. Additionally, during ESWL cardiac rhythm and blood pressure were monitored. ESWL was performed with an electromagnetic lithotriptor under light anaesthesia with intravenous diazepam (10 mg) and pethidine (75-100 mg). There were no superventricular premature systoles in any of the patients during treatment. In 15 patients with occasional ventricular premature systoles (VPS) (6-81 per 23 hours) in the 24-hour ECG the number of VPS increased during the one-hour ESWL procedure significantly to 6-55 (P less than 0.05). 14 of these patients had an unremarkable cardiac history. Changing the lithotriptor coupling angle failed to suppress the VPS in only two patients. In these two it was necessary to trigger the shock wave with the ECG. Blood pressure rose markedly (up to 220 mm Hg systolic) during ESWL in only three patients, known hypertensives. But this rise was easily controlled with nifedipine, 10 mg sublingually. These data demonstrate that ESWL is a safe alternative to operative treatment, even in the presence of existing cardiac disease. Nonetheless, precautions should be taken in case there are complications.

https://doi.org/10.1055/s-2008-1063606